Karyopharm Therapeutics to Present Clinical Data on Selective Inhibitors of Nuclear Export (SINE), KPT-330, at 2013 ASCO Annual MeetingNatick, Mass. – May 15, 2013 – Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced that clinical data for its lead drug candidate, KPT-330, in patients with advanced solid tumors will be presented in the Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics oral abstract session at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31st – June 4th, 2013 in Chicago, Illinois. KPT-330 is an oral, small molecule Selective Inhibitor of Nuclear Export (SINE) that induces cell death selectively in cancer cells through forced nuclear retention and activation of tumor suppressor proteins by blocking Exportin 1 (XPO1).
“We are honored to be making an oral presentation at ASCO on our first-in-human phase I trial of KPT-330 in solid tumors and to further demonstrate the fundamental new biology of our SINE platform,” commented Karyopharm Chief Scientific Officer and founder Sharon Shacham, Ph.D.
The presentation will highlight initial data from the dose escalation portion of the ongoing phase I study in patients with relapsed or refractory solid tumors whose disease has progressed on currently available treatments (NCT01607905). A phase I study of KPT-330 is also ongoing in hematologic malignancies (NCT01607892).
Details of the oral abstract presentation are as follows:
Abstract #2505: “First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.”
Albiruni R. Razak, MD. Princess Margaret Hospital, University Health Network, Toronto, ON.
Oral Abstract Session: Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
Sunday, June 2, 9:30-9:45 AM, Room S406
Karyopharm Therapeutics Inc. clinical-stage biopharmaceutical company founded by Drs. Sharon Shacham and Michael Kauffman in late 2008 and has emerged as a leader in the new field of nuclear transport modulators. Karyopharm’s selective inhibitors of nuclear export (SINE) function by trapping multiple tumor suppressor proteins in the nucleus, resulting in anti-cancer activity across multiple tumor types. Karyopharm’s lead SINE KPT-330 is in two Phase 1 clinical studies for advanced solid tumor and hematologic malignancies. The related SINE KPT-335 is being tested in a pivotal study as an oral treatment for dogs with Non-Hodgkin’s Lymphoma, one of the most common canine cancers. The Company is also testing SINEs in autoimmune, viral and dermatologic disorders. Karyopharm Therapeutics is located in Natick, Massachusetts.
THIS PRESS RELEASE CONTAINS ARCHIVAL INFORMATION WHICH SHOULD NOT BE CONSIDERED CURRENT AND MAY NO LONGER BE ACCURATE